Shane Ward - 10 Dec 2025 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role
COO & CLO
Signature
/s/ Shane Ward
Issuer symbol
CDTX
Transactions as of
10 Dec 2025
Net transactions value
-$5,305,990
Form type
4
Filing time
12 Dec 2025, 19:40:13 UTC
Previous filing
02 Apr 2025
Next filing
07 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ward Shane COO & CLO 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO /s/ Shane Ward 12 Dec 2025 0001638380

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDTX Common Stock Tax liability $3,303,004 -15,041 -38% $219.60 24,633 10 Dec 2025 Direct F1
transaction CDTX Common Stock Options Exercise $58,289 +3,500 +14% $16.65 28,133 10 Dec 2025 Direct
transaction CDTX Common Stock Options Exercise $130,472 +6,459 +23% $20.20 34,592 10 Dec 2025 Direct
transaction CDTX Common Stock Sale $2,191,747 -9,959 -28% $220.08 25,033 10 Dec 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDTX Employee Stock Option (right to buy) Options Exercise $0 -3,500 -100% $0.000000 0 10 Dec 2025 Common Stock 3,500 $16.65 Direct F3, F4
transaction CDTX Employee Stock Option (right to buy) Options Exercise $0 -6,459 -51% $0.000000 6,207 10 Dec 2025 Common Stock 6,459 $20.20 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld for taxes on RSU vesting.
F2 Includes 400 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP), representing 200 shares purchased on each of the following dates: May 20, 2025; and November 20, 2025.
F3 The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2022.
F4 The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
F5 The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 27, 2023.